Clinical trials: Diabetes Type II
Type 2 Diabetes Mellitus
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus® injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
- Trial name
- NCT00097500
- Testing
- exenatide, Insulin glargine, Metformin
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 69 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus
A prospective, open labeled, randomized controlled clinical trial comparing the benefit of both hyperbaric oxygen therapy and intrapancreatic stem cell infusion to standard medical treatment alone for type 2 diabetes mellitus.
- Trial name
- HOT (NCT01786707)
- Testing
- Autologous stem cells, Hyperbaric oxygen therapy, Insulin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rodolfo Alejandro
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
- Trial name
- SURPASS-SWITCH (NCT05564039)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 38 sites in United States, Belgium and 3 more
- Volunteers
- 282 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Diabetic Peripheral Neuropathy
Evaluation of Exenatide in Patients With Diabetic Neuropathy
This study will look at whether or not the medication exenatide improves signs and symptoms of diabetic peripheral neuropathy in people with type 2 diabetes and mild to moderate diabetic peripheral neuropathy.
- Trial name
- NCT00855439
- Testing
- Exenatide, Glargine
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Michigan
Diabetes Mellitus, Type 2, Hypercholesterolemia
Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)
Objective: To investigate the effect of 5 weeks dapagliflozin 10 mg once daily treatment on glucose and lipid fluxes in patients with type 2 diabetes. Study design: Single center single arm (mechanistic) intervention trial.
- Trial name
- DICE (NCT03074630)
- Testing
- Dapagliflozin, Rosuvastatin
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Amsterdam UMC, location VUmc
Diabetes Mellitus, Cancer
Diabetes Prevention Program Outcomes Study
The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired…
- Conditions
- Diabetes Mellitus, Cancer, CVD
- Trial name
- DPPOS (NCT00038727)
- Testing
- DPPOS Group Lifestyle, Metformin, DPPOS Boost Lifestyle
- Where
- United States
- Volunteers
- 2,779 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, and the United States of America (USA). The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) plus insulin aspart (IAsp)…
- Trial name
- BEGIN™ (NCT00972283)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 136 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,006 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)
This study will test the hypothesis that the Final Market Image (FMI) sitagliptin/metformin 50 mg/500 mg and 50 mg/850 mg (Fixed Dose Combination) FDC tablet and co-administration of corresponding doses of sitagliptin and…
- Trial name
- NCT01093794
- Testing
- Co-administration of 50 mg sitagliptin and 500 mg metformin, sitagliptin/metformin 50 mg/500 mg tablet, Co-administration of 50 mg sitagliptin and 850 mg metformin
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)
This study will test the effectiveness and safety of treatment with MK-0893 in combination with other drugs commonly used to treat type 2 diabetes for a duration up to 13 weeks.
- Trial name
- NCT00631488
- Testing
- MK-0893, Sitagliptin, Metformin
- Volunteers
- 146 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus, Coronary Artery Disease
Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus
Arterial stiffness is associated with increased risk for cardiovascular disease. Moreover, the integrity of endothelial glycocalyx plays a vital role in vascular permeability, inflammation and elasticity.
- Trial name
- NCT03010683
- Testing
- Liraglutide, Metformin
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Athens
Severe Insulin Resistance
Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance
Study Description: Patients with mutations of the insulin receptor have diabetes that is challenging to control with conventional therapies, leading to early morbidity and mortality.
- Trial name
- NCT00085982
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pregnancy Complications
Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes
Pregnant women with type 2 diabetes mellitus (T2DM) are at increased risk for miscarriages, birth defects, large infants, and stillbirths. Maintaining blood sugars in the normal range decreases these pregnancy complications.
- Trial name
- NCT00678080
- Testing
- Metformin, Insulin (NPH and Regular)
- Where
- 3 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Type 2 Diabetes Mellitus
A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)
The purpose of this study is to collect information of the risk profile of patients with type 2 diabetes mellitus, their treatment concerning meeting the guidelines for treatment of diabetic patients type 2 published by the…
- Trial name
- SIRTA (NCT01409213)
- Volunteers
- 1,523 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from…
- Trial name
- NCT00734474
- Testing
- LY2189265, Sitagliptin, Metformin
- Where
- 99 sites in United States, Canada and 11 more
- Volunteers
- 1,202 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Hypertension
A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension
To evaluate the impact of escalating doses of IW-1973 on endothelial function [using EndoPAT to measure fingertip small vessel pulse volume], blood pressure (BP), and heart rate.
- Trial name
- NCT02906579
- Testing
- IW-1973
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cyclerion Therapeutics
Type 2 Diabetes Mellitus
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
The purpose of the study was to demonstrate if iGlarLixi (Soliqua 100/33) would improve glycemic control (as measured by Time in Range) and glycemic variability in participants with very uncontrolled (HbA1c ≥ 9%) type 2 Diabetes…
- Trial name
- Soli-CGM (NCT05114590)
- Testing
- Insulin glargine/Lixisenatide
- Where
- 18 sites in United States
- Volunteers
- 124 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in combination with Sulfonylurea in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of…
- Trial name
- NCT00974090
- Testing
- Teneli / Teneli + SU
- Where
- Japan
- Volunteers
- 194 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type II
Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
Type 2 Diabetes Mellitus (T2DM) is a disease that interferes with the body's proper production and use of insulin, a hormone needed to convert sugar into usable energy.
- Trial name
- T2DM (NCT00577590)
- Testing
- Metformin, Rosiglitazone, Lovaza
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Washington University School of Medicine
Diabetes Mellitus, Type 2, Pre-diabetes
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans
The rationale for the proposed research is that elucidating changes in localized diacylglycerol (DAG) and sphingolipid species that predict insulin sensitivity will reveal specific localized lipids to target in therapeutics for…
- Conditions
- Diabetes Mellitus, Type 2, Pre-diabetes, Obesity
- Trial name
- NCT03077360
- Testing
- Lifestyle
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Diabetes, Diabetes Mellitus, Type 2
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes.
- Trial name
- DUAL™ I (NCT01336023)
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- 302 sites in United States, Australia and 18 more
- Volunteers
- 1,663 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.